NIH is funding many studies premised upon how little research has been conducted on the long-term health risks of cross-sex hormones.
` Author Anonymous profile ANONYMOUS MORE ARTICLES SHARE Share Article on Facebook Share Article on Twitter Share Article on Truth Social Copy Article Link Share Article via Email As the Biden administration pushes the Department of Health and Human Services to make “gender-affirming health care” more widely available, HHS`s own National Institutes of Health is funding multiple studies premised upon how little research has been conducted on the long-term risks of taking cross-sex hormones and whether they improve mental health.
Several NIH-funded studies examine specific health risks of cross-sex hormone treatment — such as associated bone loss and possible increased risk of thrombosis, drug overdose, heart attack, and stroke.
Only a few studies evaluate the risk of infertility, even though “the impact of long-term cross-sex hormone therapy on reproductive health is largely unknown,” as one such project states and experts have warned.
” Many Ongoing Projects Highlight Lack of Research While suicide prevention is often cited as a major reason to give dysphoric children puberty blockers and cross-sex hormones, only one of the current studies is focused specifically on suicide risk, although several emphasize the lack of long-term studies of cross-sex hormones administered to children and their relation to mental health.
One NIH-funded project summary acknowledges that the long-term effect of puberty suppression on mental health needs further study and will evaluate children already taking puberty blockers.
” Another research project, “Psychological consequences of medical transition in transgender youth,” begun last year at Princeton University and anticipated to end in 2025, notes the lack of quality research in this area: Five studies to date have longitudinally examined the relationship between one or both of these interventions [puberty suppression and hormone therapy] and mental health in transgender youth.
” As the summary of one ongoing NIH-funded research project on sex hormones` effects on the developing brain says, “There is little to no empirical data guiding clinical practices” of cross-sex hormone therapy in early pubertal adolescents, “highlighting the need for further research to address the critical knowledge gap.
NIH Acknowledges Limited Evidence, FDA Hasn`t Approved The NIH, the largest public funder of biomedical research in the world, told Reuters that “the evidence is limited on whether these treatments pose short- or long-term health risks for transgender and other gender-diverse adolescents.
” Additionally, the Food and Drug Administration has not approved puberty blockers and sex hormones for children`s transgender medical interventions.
No comments:
Post a Comment